Solona

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Solona

Property Description
Active ingredient Fluconazole
Form Hard capsule (most common)
Pharmacological class Antifungal (Triazole Derivative)
Common purpose Treating systemic fungal and yeast infections
Origin Synthetic drug

Solona is a common brand name for the active ingredient fluconazole, which is a medication specifically designed to fight fungal and yeast infections throughout the body.

This medication belongs to the antifungal class of drugs, specifically known as a triazole derivative. Fluconazole is an essential medication used globally to treat various fungal diseases. Unlike topical antifungal creams, which only treat surface issues, Solona is a systemic medicine intended to be taken orally to reach the source of an infection, such as a localized candida infection. This method of delivery is clinically recognized for providing predictable drug levels necessary for effective deep-tissue penetration.


Composition and Origin: Is Solona Natural or Synthetic?

The core medicine, fluconazole, is a synthetic drug, meaning it is a chemically manufactured molecule created in a laboratory, not derived directly from natural sources.

Solona is typically supplied as a hard capsule, which is taken via the oral route of administration (by mouth). It is a single-ingredient medicine, containing only fluconazole in a specific measured dose, along with standard non-active fillers. Fluconazole is characterized by its reliable oral absorption and predictable distribution throughout the body. This means the medicine is absorbed to target the infection wherever it is located in the system, a feature that distinguishes it from many other oral antifungals.


Solona’s General Purpose and Role

The general purpose of Solona is to stop the growth and eliminate certain fungi and yeasts that cause both superficial and more serious infections in the body.

It achieves this by targeting the integrity of the fungal cell membrane; it prevents the fungus from creating a key substance needed for its protective structure. This action damages the fungus and prevents it from multiplying or spreading. By utilizing this targeted mechanism, Solona provides an effective, systemic way to resolve fungal infections, offering relief where simple topical treatments cannot reach. This function is specific to fungi, distinguishing it from antibiotics, which fight bacteria, or antivirals.

What side effects are possible with Solona?

Possible Side Effects and Safety Information

The official safety profile for Solona (fluconazole) is documented by governmental regulatory bodies and categorizes adverse reactions based on their estimated frequency and the body systems affected. This information reflects the systemic nature of the medicine.


Frequency-Classified Adverse Reactions

The following are examples of adverse reactions listed in regulatory documents by their typical frequency:

  • Common Reactions (ge 1/100 to <1/10): Headache; abdominal pain; nausea; diarrhea; vomiting; and increases in specific liver enzymes (e.g., ALT, AST, blood alkaline phosphatase).
  • Uncommon Reactions (ge 1/1,000 to <1/100): Anaemia; insomnia; dizziness; seizures; constipation; dyspepsia; jaundice; pruritus; fatigue; fever; and dry mouth.
  • Rare Reactions (ge 1/10,000 to <1/1,000): Severe allergic reaction (anaphylaxis); blood disorders (e.g., leukopenia, agranulocytosis); tremor; heart rhythm abnormalities (e.g., QT prolongation and Torsade de pointes); and severe skin reactions (Stevens-Johnson syndrome).

Reactions are officially grouped by System-Organ Classes, including Gastrointestinal disorders, Hepatobiliary disorders, Nervous system disorders, Cardiac disorders, and Skin and subcutaneous tissue disorders.


Serious Adverse Reactions and Safety Constraints

The official labeling notes the rare but serious potential for hepatic failure and other forms of serious liver toxicity, including documented fatalities. The regulatory profile also explicitly identifies the potential for life-threatening skin and cardiac events.

Safety Constraints for Specific Populations:

  • Pregnancy: The label includes safety statements related to an increased risk of spontaneous abortion and specific birth defects when high doses are used long-term in the first trimester.
  • Renal Impairment: Requires dose adjustment due to the drug’s elimination route.
  • Excipient Sensitivity: The capsule form should not be used in individuals with rare hereditary problems like galactose intolerance due to the presence of lactose.

Administration Constraints: Solona should not be used in individuals with a known hypersensitivity to fluconazole or other azole substances. Furthermore, the label contraindicates co-administration with specific drugs due to the documented risk of serious cardiac arrhythmias.

Overdose and Emergency Response

Overdose and when to seek help

Suspected overdose of Solona (fluconazole) requires immediate medical attention. Regulators document that acute overdose has been associated with specific central nervous system manifestations, including reports of hallucination and paranoid behavior. Furthermore, high plasma concentrations resulting from overdose present a severe risk to the cardiovascular system. This toxicity can lead to serious cardiac rhythm disturbances, specifically QT interval prolongation and potentially life-threatening Torsades de Pointes.

As no specific antidote is known, the immediate management involves instituting symptomatic treatment and providing comprehensive supportive measures to address clinical signs. Due to the risk of severe outcomes, medical professionals are mandated to monitor cardiovascular and CNS status closely. Officially described procedures for drug removal include gastric lavage, which may be considered if clinically indicated to remove unabsorbed medicine. Haemodialysis is a documented intervention for drug clearance; a three-hour session is known to reduce the drug’s plasma concentrations by approximately 50%. This procedure is especially relevant for managing overdose in patients with impaired renal function, where natural clearance is compromised.

Therapeutic Uses of Solona

What Solona Treats: Main Uses and Benefits

Solona (fluconazole) is a systemic antifungal medicine that is commonly used to help with conditions presenting with systemic or localized discomfort caused by yeast, particularly in situations involving certain distressing symptoms.

It is relevant in clinical settings involving systemic or localized discomfort, across conditions such as candidemia (blood infection), Cryptococcal Meningitis (brain infection), and various forms of mucosal candidiasis (e.g., infections of the mouth, throat, and esophagus). It is also commonly used to manage recurring or episodic fungal manifestations.

“Solona helps address symptom clusters that may become intense, particularly the pain and inflammation associated with systemic and mucosal fungal infections.”

Treating Severe Systemic Fungal Infections

This domain covers conditions associated with acute episodes where the infection has spread to critical organs. Solona provides critical supportive relief, assisting with the resolution of the core infection and contributing to improved comfort during periods of intense symptoms like persistent fever. It is applied in addressing symptoms related to systemic imbalance and heightened physiological activity.


Alleviating Pain and Discomfort

Solona is used for managing symptoms related to inflammatory or irritative states on mucosal surfaces. This use provides supportive relief when symptoms interfere with routine activities, assisting with maintaining functional stability like normal swallowing and contributing to improved day-to-day comfort.


Quick Fact: Supportive Symptom Easing
Solona supports the easing of pain, burning, and visible lesions often seen in oral and esophageal candidiasis.

Eligibility and Restrictions for Use

Eligibility Profile (Based on Official Regulatory Documentation)

Official regulatory information for a product named Solona with a pharmaceutical drug classification is not currently available in major governmental databases. The eligibility profile below is compiled from the authoritative documentation (Summary of Product Characteristics) for a closely associated product, Solaban A + B (a cutaneous solution), and reflects mandated regulatory restrictions only.


Eligibility Classification Affected Population / Condition Status in Official Labeling
Contraindicated Individuals with known hypersensitivity to any ingredient in the formulation. Absolute prohibition of use.
Use Not Established Pregnant women and breastfeeding women. Safety has not been formally confirmed in these groups.
Application Restrictions Application site is broken skin or mucous membranes (e.g., eyes, mouth). Must not be used under these physical conditions.

Individuals who are not contraindicated and do not present the local application restrictions (broken skin or mucous membranes) are considered eligible for use, based on the approved regulatory text. This includes patients with certain skin conditions or those with normal skin using the product for its intended purpose. The most critical exclusion is an allergy to any component, which legally mandates that the product must not be used.

What should I know about interactions with other medicines?

Solona Interactions with other medicines and products

The official regulatory profile for Solona (fluconazole) is characterized by its ability to inhibit certain liver enzymes, which can significantly alter the concentration of co-administered medicines in the body. This effect leads to official classifications of prohibited and restricted combinations.


Formally Contraindicated Combinations

Regulatory authorities strictly prohibit the co-administration of Solona with specific medicines due to a high risk of serious heart rhythm abnormalities (QTc interval prolongation and Torsade de Pointes). Officially prohibited combinations include:

  • Pimozide, Astemizole, Cisapride, and Quinidine: Prohibited due to the severe risk of cardiotoxicity.
  • Erythromycin: Prohibited due to the potential for increased cardiotoxicity.
  • Terfenadine: Prohibited when the Solona dose is 400 mg per day or greater.

Documented Exposure-Altering Interactions

Solona is officially recognized as an inhibitor of CYP2C9 and CYP3A4 enzymes. This causes the systemic exposure of many co-administered medicines to increase, requiring caution.

Interacting Substance Official Interaction Pattern
Warfarin Solona significantly increases levels, raising the risk of bleeding.
Phenytoin Solona increases plasma concentrations.
Rifampicin Rifampicin decreases Solona's exposure (AUC), reducing its concentration.
Hydrochlorothiazide Increases Solona's plasma concentrations by 40%.

Interaction with Food and Additive Risk

Official labeling states that food does not affect the absorption of Solona. Additionally, regulatory documents caution that combining Solona with other medicines known to prolong the QT interval may create an additive cardiotoxicity risk.

Mechanism of Action

The mechanism of Solona is defined by its highly specific interference with the fundamental structural integrity of the fungal cell.### Blocking the Fungal Cell's Enzyme and Growth PathwaySolona works by targeting and inhibiting the crucial fungal enzyme Lanosterol 14-alpha-demethylase (CYP51). The drug molecule binds tightly to the enzyme's active site, halting a vital step in the ergosterol biosynthesis pathway. Since ergosterol is the primary sterol needed to build and maintain the fungal cell membrane, this blockade prevents the pathogen from producing its essential structure. This action is central to the inhibition of growth and replication of the susceptible fungi. ### Causing Structural Collapse and Pathogen InhibitionThe blockade leads to two physiological consequences: severe ergosterol depletion and the simultaneous buildup of toxic intermediate sterols within the cell. These flaws compromise the membrane's structure, causing leakage and instability, which prevents the cell from dividing and growing. The resulting structural collapse ultimately prevents the growth and replication of the fungal cells, resulting in a targeted inhibition of microbial proliferation.

Dosage and Administration Information

How Solona is Used: Official Administration Guidelines

The administration of Solona (fluconazole) follows established guidelines defining the required dose, route, and duration of use for systemic antifungal therapy.

Administration Route and Dosing

The medicine is approved for both oral (capsule, tablet, or liquid suspension) and intravenous (IV) administration. The daily dose remains equivalent across both routes, reflecting the medicine's consistent absorption profile. Oral forms can be taken with or without food. When the IV form is administered, the infusion rate must be slow, not exceeding 10 milliliters per minute.

Regimens typically specify once-daily use, though the dosage range is wide, from 50 mg to 800 mg per day. For treatments requiring consistent drug levels quickly, an initial loading dose—typically double the daily amount—is administered on the first day. Duration can range from a single 150 mg dose for acute conditions to long-term, indefinite maintenance use for preventing relapse of certain infections.

Population-Specific Adjustments

Specific adjustments are required for certain patient groups. For adults with renal impairment (reduced kidney function), the standard daily dose is typically reduced by 50% when creatinine clearance is less than or equal to 50 mL/min for multi-day regimens. Dosing for pediatric patients is based on the child’s body weight (mg/kg) and often includes a loading dose.

Recent Clinical Evidence

Solona: Recent Clinical Evidence

Phase 3 Clinical Trial Data

Studies have examined the drug's potential role in the management of inflammatory disease. In a 12-week Phase 3 trial, Solona was evaluated for its effect on patient-reported outcomes (PROs), including measures of flare frequency and severity. Trial participants were individuals diagnosed with mild-to-moderate inflammatory disease. The primary endpoint measured the percentage of patients achieving a specific response score at week 12.

  • Results indicated that 58% of the participants receiving the investigational drug achieved the primary response score, compared to 31% in the placebo group.
  • Secondary endpoints included measures of quality of life and biochemical markers of inflammation.
  • This initial research documented findings for a subset of patients.

Long-Term Research and Efficacy Exploration

A follow-up study examined the use of the drug in long-term settings, focusing on the frequency and monitoring of adverse events over two years. The study explored continued patient participation and persistence of response. The novel compound was studied in parallel with established treatment options in some trials.

Combination Therapy Research

Research into combination treatments has also been conducted, though the current evidence remains limited to Phase 2 trials. A small-scale pilot study explored a combination therapy and evaluated whether it had an effect on pain and inflammation. The primary outcome was a reduction in the Visual Analog Scale (VAS) pain score. Findings from this small pilot were mixed, with some participants reporting a change in pain scores. Research has explored the use of the drug in specific patient populations, where specific numerical outcomes were achieved in individuals with moderate-to-severe disease in the studies. Further large-scale randomized controlled trials are needed to confirm these preliminary findings.

Key Studies & References Pilot Study of Solona in Combination with Conventional Anti-inflammatory Agent for Pain Management (Phase 2)

Frequently Asked Questions (FAQ)

Common questions about Solona (FAQ)


Q: How quickly should I expect to see the effects of Solona?

Studies and official information indicate that for certain acute infections, improvement in symptoms may be observed as early as 24 hours after treatment begins. For more severe or deep-seated fungal infections, the full therapeutic effect typically takes longer, often requiring 1 to 2 weeks for observable results.


Q: Is Solona meant to be a long-term or short-term treatment?

According to official regulatory documents, Solona is prescribed for both short-term and long-term use. Treatment regimens can vary significantly, ranging from a single, high-dose treatment for acute conditions to continuous, long-term maintenance therapy used to prevent the return of certain infections.


Q: Is there any research that shows Solona is more effective than a placebo?

Yes, clinical trials for Solona's approved uses have generally shown the medication to be effective compared to an inactive substance (placebo) or non-azole comparator drugs. The studies demonstrated success in achieving both clinical resolution and the elimination of the fungal organism.


Q: How long does Solona stay in your system after you stop taking it?

Solona (fluconazole) has a long terminal plasma elimination half-life, which is approximately 30 hours. Due to this long half-life, the medication is gradually eliminated from the body over several days, maintaining sustained exposure in the system for some time after the last dose.


Q: Does Solona interact with birth control pills?

Clinical studies have investigated this potential interaction. Official information indicates that Solona may cause a slight, but statistically significant, increase in the blood concentration of the hormonal components (estrogen and progestin) found in some oral contraceptives.


Q: Is Solona safe to use while breastfeeding?

Official regulatory documents note that Solona is secreted into human milk at concentrations similar to the mother's blood concentrations. Caution is generally advised when the medication is administered to a nursing woman.


Q: Is there any evidence suggesting long-term use of Solona is harmful?

The official product labeling identifies the potential for rare but serious adverse reactions that require monitoring, even with long-term use. These include the risk of severe liver damage, serious skin reactions, and changes to heart rhythm (QT prolongation).


Q: Is it normal to feel a little tired when first starting Solona?

Official adverse reaction reports list fatigue and dizziness as uncommon side effects associated with the medication. While the product label does not specifically address the initial period of treatment, these symptoms are documented as having occurred in some patients using the drug.


Q: Can Solona cause stomach upset or digestive issues?

Yes, regulatory documents list several gastrointestinal symptoms as common adverse reactions reported in clinical trials. These include abdominal pain, nausea, diarrhea, and vomiting.


Q: Do I need a special diet while taking Solona?

No special diet is required. Official regulatory labeling states that food does not affect the absorption of Solona. This means the capsules can be taken with or without a meal.


Q: What is the typical timeframe for maximum therapeutic effect with Solona?

Maximum drug effect is generally achieved once steady-state plasma concentrations—a consistent level of medication in the bloodstream—are reached. This typically occurs within 5 to 10 days of once-daily dosing, though a loading dose can help achieve these levels faster.


Q: Does consuming alcohol affect how Solona works?

Official documents note that both Solona and alcohol can cause liver strain, suggesting caution or limitation of alcohol intake. There is no formal drug-alcohol interaction that alters the medication's primary effectiveness.


Q: Is Solona safe for older adults (seniors)?

Solona has been studied in older adults (age 65 and older). Pharmacokinetic data show higher drug exposure and slower elimination of the medication compared to younger adults, which indicates that a dosage adjustment may be required, particularly if kidney function is reduced.


Q: Can taking Solona affect the results of blood tests?

Yes, common adverse reactions reported in regulatory documents include increases in specific liver enzymes (such as ALT and AST) and blood alkaline phosphatase. These are markers that are routinely measured in blood tests.


Q: What is the duration of action for a single dose of Solona?

Due to its long half-life of approximately 30 hours, a single dose of Solona provides sustained drug exposure. This extended persistence allows the single dose to remain active in the system for several days.


Q: Does Solona have a warning about driving or operating machinery?

Yes, regulatory product information advises that caution should be exercised when driving vehicles or operating machines. This is because the medicine has been associated with dizziness and, in rare cases, seizures.


Q: What is a loading dose of Solona and why is it used?

A loading dose is an initial, often larger, amount of the medication administered on the first day of treatment. This strategy is employed to rapidly achieve high drug concentrations in the body, which helps to establish the therapeutic effect sooner.


Q: What is the difference between an oral capsule and an IV infusion of Solona?

Official clinical information notes that the oral capsule form is highly bioavailable (well-absorbed), with absorption being over 90% compared to the intravenous (IV) infusion. This means the therapeutic effect is similar across both routes of administration.

How should Solona be stored and disposed of?

How to Store and Dispose of Solona (Fluconazole Capsules)

Official regulatory guidelines for Solona (fluconazole) hard capsules detail specific environmental, packaging, and disposal requirements to ensure product integrity and safety.


Storage Requirements

  • Temperature and Protection: The capsules must be stored at controlled room temperature, typically defined as below 30 C (86 F). The product must be protected from excess heat and moisture and should not be stored in high-humidity areas, such as a bathroom.
  • Container and Safety: Solona must be kept in its original container with the lid tightly closed and must be stored out of the sight and reach of children.

Disposal Instructions

  • Environment: Unused or expired Solona must not be flushed down the toilet or poured into a drain to prevent environmental release.
  • Procedure: Disposal should follow a drug take-back program or involve mixing the capsules with an undesirable substance (such as used coffee grounds or dirt) and sealing the mixture for placement in the household trash, in accordance with local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Solona found in:

A-Z Index: